株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオマーカー:技術および世界市場

Biomarkers: Technologies and Global Markets

発行 BCC Research 商品コード 174949
出版日 ページ情報 英文 171 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.65円で換算しております。
Back to Top
バイオマーカー:技術および世界市場 Biomarkers: Technologies and Global Markets
出版日: 2018年08月31日 ページ情報: 英文 171 Pages
担当者のコメント
BCCリサーチより、バイオマーカーに着目した最新レポートがリリースされました。法規制動向、アプリケーション別(ゲノミクス、プロテオミクス、画像診断等)、マーカー種類別(薬剤、分子マーカー等)、疾患領域別(癌、心疾患、免疫、神経等)、様々な区分けで市場予測を分析しており、製薬会社様からの引き合いも多いレポートです。
概要

世界のバイオマーカーの市場規模は、2018年には789億米ドル、2023年には1365億米ドルと、11.6%のCAGR (複合年間成長率) で拡大するとみられています。

当レポートでは、世界のバイオマーカー市場について分析し、市場の基本構造や最新情勢、全体的な市場規模の動向見通し、分野別・製品種類別・治療領域別・地域別の市場の主な特徴や成長可能性、現在の技術開発水準今後の技術開発の方向性、主な市場促進・抑制要因、主要企業のプロファイル・主力製品といった情報を取りまとめてお届けいたします。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 概要

  • イントロダクション
  • バイオマーカー:市場のダイナミクス
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
    • 課題

第4章 規制動向、知的所有権、倫理規定

  • イントロダクション
  • バイオマーカー研究所の規制:概要
  • IVD (体外診断用医薬品) によるコンパニオン診断:定義
  • 新規技術に対する規制プロセス
    • 医療技術の安全性・効率性の確保
    • 発展途上国での分析
    • 診断薬の共同開発における、アッセイ (分析法) の開発と認証
    • 患者と対照被験者の選定
    • FDA (米国食品医薬品局) の役割
  • バイオマーカーの利用に関するFDAのガイドライン
  • EMA (欧州医薬品庁)
  • 薬剤の安全性に対する規制の影響

第5章 市場区分:分野別

  • イントロダクション
  • 市場の内訳
    • ゲノミクス用バイオマーカー
    • プロテオミクス用バイオマーカー
    • 画像診断用バイオマーカー
    • バイオインフォマティクス関連バイオマーカー

第6章 市場区分:治療領域別

  • イントロダクション
  • 市場の内訳
    • 腫瘍
    • 心臓バイオマーカー
    • 神経疾患
    • 免疫バイオマーカー

第7章 市場区分:種類別

  • イントロダクション
  • 市場の内訳
    • 疾患関連バイオマーカー
    • 薬剤関連バイオマーカー
    • 分子バイオマーカー
    • 代替バイオマーカー

第8章 市場区分:地域別

  • イントロダクション
  • 市場の内訳
    • 概要
    • 北米
    • 欧州
    • アジア太平洋地域
    • その他

第9章 競争環境と主な動向

  • 主要企業と市場構造の分析
  • 近年の主な動き
  • 医薬品パイプラインの分析:主要メーカー別
    • Abbott Laboratories
    • Astellas Pharma
    • AstraZeneca
    • Bayer Group
    • Boehringer Ingelheim
    • 第一三共
    • Eli Lilly and Company
    • Novartis
    • Pfizer
    • Sanofi-Aventis
    • 武田薬品工業
    • Teva Pharmaceutical

第10章 企業プロファイル

  • ABBOTT LABORATORIES
    • 事業概要
      • 財務分析
    • 主要製品・サービス
  • AFFYMETRIX, INC.
  • アステラス製薬
  • ASTRAZENECA PLC
  • BANYAN BIOMARKERS, INC.
  • BAYER GROUP
  • BG MEDICINE
  • BIOSYSTEMS INTERNATIONAL
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB
  • CAPRION PROTEOMICS INC.
  • 第一三共
  • エーザイ
  • ELI LILLY AND CO.
  • EPIGENOMICS AG
  • GENEDATA AG
  • GENENEWS LTD.
  • GLAXOSMITHKLINE
  • JOHNSON & JOHNSON
  • MERCK & CO.
  • NOVARTIS AG
  • PFIZER, INC.
  • QIAGEN N.V.
  • F. HOFFMANN-LA ROCHE LTD.
  • SANOFI-AVENTIS
  • 武田薬品工業
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
図表

List of Tables

  • Summary Table A: Global Market for Biomarkers, by Segment, Through 2023
  • Summary Table B: Global Market for Biomarkers, by Type, Through 2023
  • Summary Table C: Global Market for Biomarkers, by Therapeutic Area, Through 2023
  • Summary Table D: Global Market for Biomarkers, by Region, Through 2023
  • Table 1: Notable NIH Grants for Biomarker Related Projects, 2018
  • Table 2: Global Market for Biomarkers, by Segment, Through 2023
  • Table 3: Global Market for Genomic Biomarkers, by Country/Region, Through 2023
  • Table 4: Global Market for Proteomics Biomarkers, by Country/Region, Through 2023
  • Table 5: Global Market for Imaging Biomarkers, by Country/Region, Through 2023
  • Table 6: Global Market for Bioinformatics Related Biomarkers, by Country/Region, Through 2023
  • Table 7: Global Market for Biomarkers, by Therapeutic Area, Through 2023
  • Table 8: Global Market for Biomarkers in Oncology, by Country/Region, Through 2023
  • Table 9: Global Market for Biomarkers in Cardiology, by Country/Region, Through 2023
  • Table 10: Global Market for Biomarkers in Neurology, by Country/Region, Through 2023
  • Table 11: Global Market for Biomarkers in Immunology, by Country/Region, Through 2023
  • Table 12: Global Market for Biomarkers, by Type, Through 2023
  • Table 13: Global Market for Biomarkers, by Region, Through 2023
  • Table 14: North American Market for Biomarkers, by Country, Through 2023
  • Table 15: North American Market for Biomarkers, by Segment, Through 2023
  • Table 16: North American Market for Biomarkers, by Therapeutic Area, Through 2023
  • Table 17: U.S. Market for Biomarkers, by Segment, Through 2023
  • Table 18: U.S. Market for Biomarkers, by Therapeutic Area, Through 2023
  • Table 19: Canadian Market for Biomarkers, by Segment, Through 2023
  • Table 20: Canadian Market for Biomarkers, by Therapeutic Area, Through 2023
  • Table 21: Mexican Market for Biomarkers, by Segment, Through 2023
  • Table 22: Mexican Market for Biomarkers, by Therapeutic Area, Through 2023
  • Table 23: European Market for Biomarkers, by Country, Through 2023
  • Table 24: European Market for Biomarkers, by Segment, Through 2023
  • Table 25: European Market for Biomarkers, by Therapeutic Area, Through 2023
  • Table 26: German Market for Biomarkers, by Segment, Through 2023
  • Table 27: German Market for Biomarkers, by Therapeutic Area, Through 2023
  • Table 28: French Market for Biomarkers, by Segment, Through 2023
  • Table 29: French Market for Biomarkers, by Therapeutic Area, Through 2023
  • Table 30: U.K. Market for Biomarkers, by Segment, Through 2023
  • Table 31: U.K. Market for Biomarkers, by Therapeutic Area, Through 2023
  • Table 32: Rest of the European Market for Biomarkers, by Segment, Through 2023
  • Table 33: Rest of the European Market for Biomarkers, by Therapeutic Area, Through 2023
  • Table 34: Asia-Pacific Market for Biomarkers, by Country, Through 2023
  • Table 35: Asia-Pacific Market for Biomarkers, by Segment, Through 2023
  • Table 36: Asia-Pacific Market for Biomarkers, by Therapeutic Area, Through 2023
  • Table 37: Japanese Market for Biomarkers, by Segment, Through 2023
  • Table 38: Japanese Market for Biomarkers, by Therapeutic Area, Through 2023
  • Table 39: Chinese Market for Biomarkers, by Segment, Through 2023
  • Table 40: Chinese Market for Biomarkers, by Therapeutic Area, Through 2023
  • Table 41: Indian Market for Biomarkers, by Segment, Through 2023
  • Table 42: Indian Market for Biomarkers, by Therapeutic Area, Through 2023
  • Table 43: Rest of Asia-Pacific Market for Biomarkers, by Segment, Through 2023
  • Table 44: Rest of Asia-Pacific Market for Biomarkers, by Therapeutic Area, Through 2023
  • Table 45: Rest of the World Market for Biomarkers by Region, Through 2023
  • Table 46: Rest of the World Market for Biomarkers, by Segment, Through 2023
  • Table 47: Rest of the World Market for Biomarkers, by Therapeutic Area, Through 2023
  • Table 48: Global Ranking of Manufacturers in Biomarkers, 2017
  • Table 49: Abbott Laboratories: Mergers, Acquisitions and Product Launches
  • Table 50: Astellas Pharma: Mergers, Acquisitions and Product Launches
  • Table 51: Astra Zeneca: Mergers, Acquisitions and Product Launches
  • Table 52: Banyan Biomarkers: Product Launches
  • Table 53: Bristol Myers Squibb: Mergers, Acquisitions and Product Launches
  • Table 54: Caprion Proteomics: Mergers, Acquisitions and Product Launches
  • Table 55: Eisai Co.: Mergers and Acquisitions
  • Table 56: GeneNews: Product Launches
  • Table 57: Merck & Co: Product Launches
  • Table 58: Qiagen: Partnerships
  • Table 59: Abbott Laboratories: Biomarkers and Pipeline
  • Table 60: Astellas Pharma: R&D Pipeline, As of April 2018
  • Table 61: AstraZeneca: Late-Stage Pipeline 2018 and 2019
  • Table 62: Bayer Group: R&D Pipeline, As of April 2018
  • Table 63: Daiichi Sankyo: Major R&D Pipeline
  • Table 64: Eli Lilly and Co.: Medicines in Development
  • Table 65: Novartis: Global Product Pipeline, As of April 2018
  • Table 66: Sanofi-Aventis: Representative Clinical Trials Involving Biomarkers
  • Table 67: Sanofi-Aventis: R&D Pipeline
  • Table 68: Takeda Pharmaceuticals: Key Products and Pipeline
  • Table 69: Teva Pharmaceutical: Specialty R&D Pipeline
  • Table 70: Abbott Laboratories: Financials, 2016-2017
  • Table 71: Abbott Laboratories: Products
  • Table 72: Affymetrix, Inc.: Representative Clinical Trials Involving Biomarkers
  • Table 73: Astellas Pharma: Financials, 2016-2017
  • Table 74: Astellas Pharma: Representative Clinical Trials Involving Biomarkers
  • Table 75: AstraZeneca: Financials, 2016-2017
  • Table 76: AstraZeneca: Representative Clinical Trials Involving Biomarkers
  • Table 77: Banyan Biomarkers, Inc.: Representative Clinical Trials Involving Biomarkers
  • Table 78: Bayer Group: Financials, 2016-2017
  • Table 79: Bayer Schering: Representative Clinical Trials Involving Biomarkers
  • Table 80: BioSystems: Representative Clinical Trials Involving Biomarkers
  • Table 81: Boehringer: Financials, 2016-2017
  • Table 82: Bristol-Myers Squibb: Financials, 2016-2017
  • Table 83: Bristol-Myers Squibb: Representative Clinical Trials Involving Biomarkers
  • Table 84: Daiichi Sankyo Co., Ltd.: Recent Financials, 2016-2017
  • Table 85: Daiichi Sankyo Co., Ltd.: Representative Clinical Trials Involving Biomarkers
  • Table 86: Eisai Co., Ltd.: Recent Financials, 2016-2017
  • Table 87: Eisai Co., Ltd.: Representative Clinical Trials Involving Biomarkers
  • Table 88: Eli Lilly and Co.: Recent Financials, 2016 and 2017
  • Table 89: Eli Lilly and Co.: Representative Clinical Trials Involving Biomarkers
  • Table 90: Epigenomics AG: Recent Financials, 2016-2017
  • Table 91: Epigenomics AG: Representative Clinical Trials Involving Biomarkers
  • Table 92: Genedata AG: Representative Clinical Trials Involving Biomarkers
  • Table 93: GlaxoSmithKline: Recent Financials, 2016-2017
  • Table 94: GlaxoSmithKline: Representative Clinical Trials Involving Biomarkers
  • Table 95: Johnson & Johnson: Recent Financials, 2016-2017
  • Table 96: Johnson & Johnson: Representative Clinical Trials Involving Biomarkers
  • Table 97: Merck & Co.: Recent Financials, 2016-2017
  • Table 98: Merck & Co.: Representative Clinical Trials Involving Biomarkers
  • Table 99: Novartis AG: Financials, 2016-2017
  • Table 100: Pfizer, Inc.: Recent Financials, 2016-2017
  • Table 101: Pfizer, Inc.: Representative Clinical Trials Involving Biomarkers
  • Table 102: Qiagen N.V.: Recent Financials, 2016-2017
  • Table 103: Roche: Recent Financials, 2016-2017
  • Table 104: Roche: Representative Clinical Trials Involving Biomarkers
  • Table 105: Sanofi: Recent Financials, 2016-2017
  • Table 106: Sanofi: Representative Clinical Trials Involving Biomarkers
  • Table 107: Takeda Pharmaceutical: Recent Financials, 2016-2017
  • Table 108: Teva Pharmaceutical: Recent Financials, 2016-2017

List of Figures

  • Summary Figure: Global Market Shares for Biomarkers, by Region, 2017 vs. 2023
  • Figure 1: Global Prevalence of Cancer, 2016
  • Figure 2: Number of Companies with Active Pipelines, 2001-2017
  • Figure 3: Global Market Share for Biomarkers, by Region, 2017
  • Figure 4: Global Market for Biomarkers, by Region, 2018 vs. 2023
  • Figure 5: Abbott Laboratories: Revenue Share and Financials, 2015-2017
  • Figure 6: Abbott Laboratories: Revenue Share, by Segment, 2017
  • Figure 7: Abbott Laboratories: Revenue Share, by Region, 2017
  • Figure 8: Astellas Pharma.: Revenue Share and Financials, 2015-2017
  • Figure 9: Astellas Pharma.: Revenue Share, by Type of Product and Service, 2017
  • Figure 10: Astellas Pharma.: Revenue Share, by Region, 2017
  • Figure 11: AstraZeneca: Revenue Share and Financials, 2015-2017
  • Figure 12: AstraZeneca: Revenue Share, by Segment, 2017
  • Figure 13: AstraZeneca: Revenue Share, by Region, 2017
  • Figure 14: Bayer Group: Revenue Share and Financials, 2015-2017
  • Figure 15: Bayer Group: Revenue Share, by Segment, 2017
  • Figure 16: Bayer Group: Revenue Share, by Region, 2017
  • Figure 17: Boehringer: Revenue Share and Financials, 2015-2017
  • Figure 18: Boehringer: Revenue Share, by Segment, 2017
  • Figure 19: Boehringer: Revenue Share, by Region, 2017
  • Figure 20: Bristol-Myers Squibb: Revenue Share and Financials, 2015-2017
  • Figure 21: Bristol-Myers Squibb: Revenue Share, by Region, 2017
  • Figure 22: Daiichi Sankyo Co., Ltd.: Revenue Share and Financials, 2015-2017
  • Figure 23: Daiichi Sankyo Co., Ltd.: Revenue Share, by segment, 2017
  • Figure 24: Daiichi Sankyo Co., Ltd.: Revenue Share, by Region, 2017
  • Figure 25: Eisai Co., Ltd.: Revenue Share and Financials, 2015-2017
  • Figure 26: Eisai Co., Ltd.: Revenue Share, by Segment, 2017
  • Figure 27: Eisai Co., Ltd.: Revenue Share, by Region, 2017
  • Figure 28: Eli Lilly and Co.: Revenue Share and Financials, 2015-2017
  • Figure 29: Eli Lilly and Co.: Revenue Share, by Therapeutic Area, 2017
  • Figure 30: Eli Lilly and Co.: Revenue Share, by Region, 2017
  • Figure 31: Epigenomics AG: Revenue Share and Financials, 2015-2017
  • Figure 32: Epigenomics AG: Revenue Share, by Region, 2017
  • Figure 33: GlaxoSmithKline: Revenue Share and Financials, 2015-2017
  • Figure 34: GlaxoSmithKline: Revenue Share, by Segment, 2017
  • Figure 35: GlaxoSmithKline: Revenue Share, by Region, 2017
  • Figure 36: Johnson & Johnson: Revenue Share and Financials, 2015-2017
  • Figure 37: Johnson & Johnson, Revenue Share, by Segment, 2017
  • Figure 38: Johnson & Johnson: Revenue Share, by Region, 2017
  • Figure 39: Merck & Co.: Revenue Share and Financials, 2015-2017
  • Figure 40: Merck & Co.: Revenue Share, by Segment, 2017
  • Figure 41: Merck & Co.: Revenue Share, by Region, 2017
  • Figure 42: Novartis AG: Revenue Share and Financials, 2015-2017
  • Figure 43: Novartis AG: Revenue Share, by Segment, 2017
  • Figure 44: Novartis AG: Revenue Share, by Region, 2017
  • Figure 45: Pfizer, Inc.: Revenue Share and Financials, 2015-2017
  • Figure 46: Pfizer, Inc.: Revenue Share, by Segment, 2017
  • Figure 47: Pfizer, Inc.: Revenue Share, by Region, 2017
  • Figure 48: Qiagen N.V.: Revenue Share, Financials, 2015-2017
  • Figure 49: Qiagen N.V.: Revenue Share, by Segment, 2017
  • Figure 50: Qiagen N.V.: Revenue Share, by Region, 2017
  • Figure 51: Roche: Revenue Share and Financials, 2015-2017
  • Figure 52: Roche: Revenue Share, by Segment, 2017
  • Figure 53: Roche: Revenue Share, by Region, 2017
  • Figure 54: Sanofi: Revenue Share and Financials, 2015-2017
  • Figure 55: Sanofi: Revenue Share, by Segment, 2017
  • Figure 56: Sanofi: Revenue Share, by Region, 2017
  • Figure 57: Takeda Pharmaceutical: Recent Financials, 2015-2017
  • Figure 58: Takeda Pharmaceutical: Revenue Share, by Region, 2017
  • Figure 59: Teva Pharmaceutical: Revenue Share and Financials, 2015-2017
  • Figure 60: Teva Pharmaceutical: Revenue Share, by Segment, 2017
  • Figure 61: Teva Pharmaceutical: Revenue Share, by Region, 2017
目次
Product Code: BIO061E

Report Highlights:

The global market for biomarkers should grow from $78.9 billion in 2018 to $136.5 billion by 2023 at a compound annual growth rate (CAGR) of 11.6% from 2018 through 2023.

North American market for biomarkers should grow from $33.1 billion in 2018 to $57.6 billion by 2023 at a CAGR of 11.8% from 2018 through 2023.

Asia-Pacific market for biomarkers should grow from $16.5 billion in 2018 to over $33.3 billion by 2023 at a CAGR of 15.1% from 2018 through 2023.

Report Scope:

Current and projected biomarker market forecasts for the forecast period 2018 to 2023 are discussed. Products approved in the last three years by the U.S. Food and Drug Administration and products expected to be approved within the forecast period are projected. Due to the timing of this report, 2018 figures are estimated except where actual results have been reported.

This report includes an analysis of the leading and emerging competitors in the current worldwide biomarkers market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define specific product strategies that were employed. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care. Detailed profiles of the current market leaders, as well as companies with innovative products poised to advance within forecast period, are discussed.

In this report, market size and forecasts by segment, type, therapeutic area and geography from 2018 through 2023 have been provided. The study is arranged to offer an overview of the biomarkers market accompanied by product, company, geographic region or country. Virtually the entire globe is covered to include prevalent data for each disease subsegment. The report encompasses the use of major types of biomarkers for clinical and research applications. In addition, major applications that are being commercialized and developed by a wide range of companies, especially for drug discovery and development processes, are also considered. The application of biomarkers in the field of diagnostics and therapeutics for major indications such as cancer, immunological disorders, neurological disorders and others are also discussed.

Excluded from this report are over-the-counter (OTC) medications and other consumables that do not require a physician's prescription.

Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.

All market share data are presented on a global basis unless specifically noted.

Report Includes:

  • 70 data tables and 42 additional tables
  • Industry analysis of the global biomarkers market
  • Country specific data and analysis for United States, Canada, Mexico, France, Germany, U.K., China, India, Japan, Middle East and Africa
  • Characterization and quantification of the market potential for biomarkers by segment, product type, therapeutic area and geographical region
  • Encompassing details of major types of biomarkers and their use in clinical and research applications
  • Examination of regional market dynamics with a focus on regulatory development, key technology updates and major drivers impacting the global market
  • Assessment of the leading biotechnology companies poised to introduce products during the forecast period, and their impact on the face of the competitive environment
  • Detailed profiles of the leading biomarkers' manufacturers, including Abbott Laboratories, Bayer Group, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline and Novartis AG

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Intended Audience
  • Methodology and Information Sources
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

  • Market Context for Biomarkers

Chapter 3 Overview

  • Introduction
  • Biomarkers: Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
  • Challenges

Chapter 4 Regulatory Dynamics, Intellectual Property and Ethical Considerations

  • Introduction
  • Biomarker Laboratory Regulatory Summary
  • Definition of An IVD Companion Diagnostic
  • Regulatory Processes for New Technologies
  • Ensuring Safety and Effectiveness of Health Technologies
  • Review in The Developing World
  • Assay Development and Validation in Drug Diagnostic Co-development
  • Selection of Patients and Controls
  • Role of the Food and Drug Administration
  • FDA Guidelines for Biomarker Applications
  • European Medicines Agency
  • Regulatory Impact on Drug Safety

Chapter 5 Market Breakdown by Segment

  • Introduction
  • Market Breakdown
  • Genomic Biomarkers
  • Proteomic Biomarkers
  • Imaging Biomarkers
  • Bioinformatics Related Biomarkers

Chapter 6 Market Breakdown by Therapeutic Area

  • Introduction
  • Market Breakdown
  • Oncology
  • Cardiology Biomarkers
  • Neurology
  • Immunology Biomarkers

Chapter 7 Market Breakdown by Type

  • Introduction
  • Market Breakdown
  • Disease-related Biomarkers
  • Drug-related Biomarkers
  • Molecular Biomarkers
  • Surrogate Biomarkers

Chapter 8 Market Breakdown by Region

  • Introduction
  • Regional Analysis
  • Overview
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 9 Competitive Landscape and Key Developments

  • Major Players and Market Structure Analysis
  • Key Developments
  • Drug Pipeline Analysis by Leading Manufacturers
  • Abbott Laboratories
  • Astellas Pharma
  • AstraZeneca
  • Bayer Group
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • Eli Lilly and Company
  • Novartis
  • Pfizer
  • Sanofi-Aventis
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical

Chapter 10 Company Profiles

  • ABBOTT LABORATORIES
  • Business Overview
    • Financials
  • Products and Services
  • AFFYMETRIX, INC.
  • Business Overview
  • Products and Services
  • ASTELLAS PHARMA, INC.
  • Business Overview
    • Financials
  • Products and Services
  • ASTRAZENECA PLC
  • Business Overview
    • Financials
  • Products and Services
  • BANYAN BIOMARKERS, INC.
  • Business Overview
  • Products and Services
  • BAYER GROUP
  • Business Overview
    • Financials
  • Products and Services
  • BG MEDICINE
  • Business Overview
  • Products and Services
  • BIOSYSTEMS INTERNATIONAL
  • Business Overview
  • Products
  • BOEHRINGER INGELHEIM GMBH
  • Business Overview
    • Financials
  • Products and Services
  • BRISTOL-MYERS SQUIBB
  • Business Overview
    • Financials
  • Products and Services
  • CAPRION PROTEOMICS INC.
  • Business Overview
  • Product and Services
  • DAIICHI SANKYO CO., LTD.
  • Business Overview
    • Financials
  • Products and Services
  • EISAI CO., LTD.
  • Business Overview
    • Financials
  • Products and Services
  • ELI LILLY AND CO.
  • Business Overview
    • Financials
  • Products and Services
  • EPIGENOMICS AG
  • Business Overview
    • Financials
  • Products and Services
  • GENEDATA AG
  • Business Overview
  • Products and Services
  • GENENEWS LTD.
  • Business Overview
  • Products and Services
  • GLAXOSMITHKLINE
  • Business Overview
    • Financials
  • Products and Services
  • JOHNSON & JOHNSON
  • Business Overview
    • Financials
  • Products and Services
  • MERCK & CO.
  • Business Overview
    • Financials
  • Products and Services
  • NOVARTIS AG
  • Business Overview
    • Financials
  • PFIZER, INC.
  • Business Overview
    • Financials
  • Products and Services
  • QIAGEN N.V.
  • Business Overview
    • Financials
  • F. HOFFMANN-LA ROCHE LTD.
  • Business Overview
    • Financials
  • Products and Services
  • SANOFI-AVENTIS
  • Business Overview
    • Financials
  • Products and Services
  • TAKEDA PHARMACEUTICALS CO. LTD.
  • Business Overview
    • Financials
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • Business Overview
    • Financials
Back to Top